European Commission approves Merck’s Keytruda as part of a treatment regimen for adults with resectable LA-HNSCC expressing PD-L1: Rahway, New Jersey Thursday, October 30, 2025, ...
Researchers have discovered that targeting PD-L1 recycling in myeloid cells enhances T-cell activation and boosts the effects ...
Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard ...
Q3 2025 Earnings Call Transcript November 3, 2025 BioNTech SE misses on earnings expectations. Reported EPS is $-0.14 EPS, ...
The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...
News Medical on MSN
Boosting First Responder Cells May Aid Cancer Therapy
Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard ...
OncoHost, a global leader in precision oncology and proteomics-based biomarker development, today announced the presentation of two new research posters at the 2025 International Society for Liquid ...
Libtayo® (cemiplimab for injection) Now Reimbursed in Québec for Advanced Non-Small Cell Lung Cancer
TORONTO, Oct. 30, 2025 /CNW/ - Regeneron Canada Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by Régie de l'assurance ...
Regeneron Canada Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by public drug programs in Ontario, British Columbia, Saskatchewan, Nova Scotia, Newfoundland and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback